Cigna Group (CI) — Company Overview and Financial Profile Cigna Group (CI) is a global health services and insurance provider offering medical, pharmacy, dental and related benefits, with a financial profile marked by solid per‑share top‑line growth, strong operating cash generation, conservative net leverage and volatile reported earnings. Revenue Growth and Financial Metrics The company’s revenu
Cigna Group (CI) is a global health services and insurance provider offering medical, pharmacy, dental and related benefits, with a financial profile marked by solid per‑share top‑line growth, strong operating cash generation, conservative net leverage and volatile reported earnings.
The company’s revenue momentum is clear: split‑adjusted revenue per share rose to $1,023.60 with 11.2% 1‑year growth and a five‑year revenue‑per‑share CAGR of about 11.38% (EPS Diluted & Revenue per Share; Revenue & EPS Growth). Total quarterly revenue reached $72.47B in the most recent quarter (Revenue & Net Income).
Financial quality metrics are supportive: trailing‑12‑month operating cash flow was $9.60B versus net income of $5.96B (a cash‑over‑earnings gap of roughly $3.64B) and operating cash has shown a rebound from mid‑2025 lows (Earnings Quality Analysis; Strategic Capital Allocation).
The company’s operating margin remains elevated around 16.48% and gross margin sits near 21.8% (Profit Margin Trends), while measured leverage is conservative (debt/e‑quity ≈ 0.0142 and interest coverage ≈ 6.83x) and the trailing P/E is about 12.4x (Price-to-Earnings (PE) Ratio Trend).
Areas of concern include pronounced earnings volatility and liquidity metrics. Diluted EPS growth turned deeply negative in the reported periods (most recently shown at about -38.7% year‑over‑year on the available series) even as revenue per share remained positive, and diluted EPS only recovered to $22.18 by the latest reported quarter (EPS Diluted & Revenue per Share; Revenue & EPS Growth).
Net profit margin is thin at roughly 2.2% and the current ratio is below 1.0 at about 0.8486, signaling short‑term liquidity pressure despite low leverage (Profit Margin Trends).
Key fundamentals to watch going forward are revenue‑per‑share growth (current level $1,023.60 and 11.2% y/y), sequential diluted EPS growth and stabilization (recent EPS $22.18, prior y/y -38.7%) and the operating cash flow versus net income gap (OCF TTM $9.60B vs net income TTM $5.96B).
Also monitor operating margin trends around the mid‑teens, the current ratio (~0.85) for liquidity, and ROE movements and P/E valuation dynamics (Return on Equity (ROE); Price-to-Earnings (PE) Ratio).
The foundation of business quality and long-term value creation
Cigna Group's revenue shows a clear upward trend over the period shown, accelerating in the last two years. Revenue moved from the mid-$40s billions in 2021–2022 to about $51.11B in Q4 2023 and continued rising through 2024–2025, advancing sequentially in 2025 from $65.50B in Q1 to $72.47B in Q4, with only a small dip between 2024-12 ($65.65B) and 2025-03 ($65.50B).
Net income is more volatile than revenue, with several notable inflection points: a net loss of -212.0M in 2024 Q1 and large peaks in 2020-12 ($4.14B) and 2022-09 ($2.78B). In 2025 net income increased from 1.41B in Q1 to 1.97B in Q3 before declining to 943.0M in Q4 2025. The most recent quarterly revenue was $72.47B. The most recent quarterly net income was 943.0M.
Why Growth Matters
Consistent revenue and earnings growth are the lifeblood of successful long-term investments. Companies that can grow their top line (revenue) and bottom line (net income) over many years demonstrate they have products or services customers value and are willing to pay for repeatedly.
Revenue Growth shows whether the company is expanding its market reach, gaining market share, or successfully launching new products.Net Income Growth demonstrates the company can convert that revenue into actual profits while managing costs effectively.
Look for steady, sustainable growth rather than erratic spikes. The best businesses compound earnings year after year, creating tremendous value for shareholders over time. Companies that can grow earnings faster than revenue are improving their profitability—a sign of operational excellence and competitive strength.
Year-over-year growth rates for revenue and earnings per share
Reading the Growth Rate Chart
This chart converts the absolute per-share figures into year-over-year percentage changes, making it easy to see whether growth is accelerating, decelerating, or reverting to trend — regardless of the company's absolute size.
Revenue per Share Growth (1-year, split-adjusted) measures how quickly the top line is expanding on a per-share basis. Sustained positive growth signals that the company continues to win customers and grow its addressable market.EPS Diluted Growth (1-year, split-adjusted) measures how quickly earnings are compounding for each shareholder. When EPS growth consistently outpaces revenue growth, operating leverage and margin expansion are at work.
Look for consistency, not just magnitude. A company that reliably grows EPS 10–15% per year is far more valuable than one that alternates between 50% spikes and deep contractions. Negative EPS growth during a period of positive revenue growth is a red flag — costs are rising faster than sales. Quarters where both lines converge near zero or go negative deserve close scrutiny.
How revenue converts to net income for the most recent annual period
Period Information
Report Type: Annual (10-K)
Period: Jan 2025 to Dec 2025
Revenue composition by disclosure category for the latest period
Revenue generated from premiums paid for insurance coverage, explicitly referenced as "premiums" in the filing.
Revenue from products and services designed to enhance the accessibility, affordability, and transparency of healthcare, described as "products and services".
Services provided to payors, including those participating in government-sponsored programs, explicitly referenced.
Revenue from managing medical practices, explicitly referenced as "managing medical practices".
Revenue from operating retail and clinical care facilities, including pharmacies and onsite clinics, explicitly referenced as "operating pharmacies, onsite clinics and other types of medical facilities".
Pharmacy-related activities tied to pharmacy providers and networks, explicitly referenced as "the pharmacy provider marketplace or pharmacy networks".
Activities and arrangements involving pharmaceutical manufacturers, including relationships and payments or discounts, explicitly referenced.
Customers, including those we serve, generally referred to as "customers".
Payors, including those participating in government-sponsored programs, explicitly referenced.
Broadly referenced as part of the customer profile within healthcare payors.
Explicitly including physicians, hospitals, and other health service providers.
Referenced as part of the customer profile.
Explicitly referenced as part of the customer profile.
Referenced as part of the customer profile.
Participants in government-sponsored programs explicitly referenced.
Operations spanning multiple countries, explicitly referenced.
Risks associated with foreign jurisdictions, including restrictions that prevent inspections, explicitly referenced.
Engagements and relationships with producers and consultants explicitly referenced.
Reliance on third-party relationships and engagements explicitly referenced.
Providing services to payors involved in government-sponsored programs explicitly referenced.
As distribution and fulfillment channels, explicitly referenced.
The filing explicitly mentions revenue items such as premiums, payments for services, and claims, and participation in government programs. It does not explicitly classify these as recurring or one-time revenue.
Dependence on relationships with pharmaceutical manufacturers, pharmacy networks, health care payors, physicians, hospitals, producers, consultants, and third parties, explicitly referenced. Also, risks related to government program participation, reinsurers, financial ratings, regulations, medical and facility operations, strategic transactions, and multinational risks are explicitly stated.
Analyzing long-term margin stability and competitive positioning
Cigna Group's gross and operating margins show a clear downward trend over the multi-year series, with gross margin falling from the mid-30s in 2019–2020 to the low-20s by the end of 2025, and operating margin sliding from the mid-20s in 2020–2021 to the mid-teens in 2025. The decline is steady rather than episodic, with notable inflection after 2021 when both gross and operating margins began a sustained descent; across 2025 the company reported sequential quarterly declines in gross margin (25.8% → 24.3% → 23.1% → 21.8%) and operating margin (19.8% → 18.6% → 17.5% → 16.5%).
Net profit margin has been more volatile: it peaked around 5.3% at 2020-12-31, declined into the high single digits/low single digits through 2022–2024, reached a low of 1.4% at 2024-09-30, and recovered modestly to 2.2% by 2025-12-31. The most recent gross margin was 21.8%, the most recent operating margin was 16.5%, and the most recent net profit margin was 2.2%.
Understanding Profit Margins
Between Jan 2025 and Dec 2025, Cigna Group converts every dollar of revenue through the following stages:
Sustainable competitive advantages reveal themselves through consistently superior profit margins over extended periods. Companies with durable economic moats maintain pricing power and operational efficiency that competitors struggle to match.
A sign of durable competitive advantage is earning sustained higher margins than competitors.Look for margins that remain stable or improve over time, especially during economic downturns. Declining margins may signal increasing competition, pricing pressure, or deteriorating business fundamentals.
Comparing reported earnings to actual cash generation
Over the period shown, Cigna Group's trailing‑12‑month operating cash flow has generally been higher than trailing‑12‑month net income, with both series showing material volatility. Operating cash flow peaked around 2023 (values above $11B–$12B) before declining into 2024–mid‑2025 and then recovering through late 2025. Net income also varied, with lower TTM amounts near $3.3B–$4.0B in 2024 and a rise into the mid‑$5B range by the end of 2025.
At the most recent 2025‑12‑31 TTM, operating cash flow remains above net income, creating a gap of about $3.64B. The most recent Operating Cash Flow (TTM) was $9.60B. The most recent Net Income (TTM) was $5.96B.
The Earnings vs. Cash Flow Gap
Reported earnings (Net Income) doesn't always reflect actual cash generation. Companies use accrual accounting, which recognizes revenue when earned and expenses when incurred—not when cash actually changes hands. This creates timing differences and opportunities for accounting discretion that can mask underlying business health.
Net Income (the "earnings" number) can be influenced by non-cash items like depreciation, stock-based compensation, and changes in accounting estimates.Operating Cash Flow, however, shows the actual cash the business generates from its core operations—a harder number to manipulate.
What to Look For
Key Insight: Companies with durable competitive advantages typically show operating cash flow that meets or exceeds net income over time, demonstrating they convert accounting profits into actual cash that can be returned to shareholders or reinvested in the business.
Measuring management's efficiency at generating profits from shareholder capital
Cigna Group's ROE moved lower through 2023 into 2024, falling from 11.6% at 2023-12-31 to 9.4% (2024-03-31), 9.6% (2024-06-30) and 8.0% (2024-09-30), then rose materially to 14.3% by the most recent quarter ending 2025-12-31. The most recent movement represents a notable rebound relative to the 2024 trough and returns ROE closer to the mid-teens after a period of sub-10% readings.
Over the multi-year series, ROE shows clear inflection points: a low of 6.4% at 2018-12-31, a high cluster around 16%—17.8% in 2020–2021 (peak 17.8% at 2021-09-30), and the trough at 8.0% on 2024-09-30 before the 2025 recovery. The most recent ROE (period end 2025-12-31) was 14.3%.
The Gold Standard of Profitability
Return on Equity (ROE) is a powerful measure of how effectively a company's management is using the money shareholders have invested. Calculated by dividing Net Income by Shareholders' Equity, it reveals how much profit is generated for every dollar of equity capital.
A consistently high ROE (typically above 15-20%) is often the signature of a "quality" business with a durable competitive advantage. It indicates that the company can generate high returns on its own capital, which it can then reinvest at these high rates to compound value over time.
What to Look For:
How the company generates and deploys its cash
Cigna Group's operating cash flow (TTM) has remained positive throughout the period shown, with higher readings in 2022–2023 (peaks around $12.9B and $12.45B) and a dip into mid-2025 (down to $5.29B at 2025-06-30) followed by a recovery through the back half of 2025 to $9.60B at 2025-12-31. The most recent trend in operating cash shows a rebound from the mid-2025 low, with the latest available operating cash flow TTM above \$9B.
Investing cash flow (TTM) moved from smaller outflows and occasional small positive readings in 2023–mid-2024 into progressively larger outflows in late 2025 and early 2026, reaching a larger negative value most recently.
Financing cash flow (TTM) has been persistently negative across the series, with very large outflows in 2021–2023 and more moderate but still substantial outflows in 2024–2025; the most recent financing TTM remains a sizable negative.
Recent Cash Flows:
Understanding Company Strategy
Capital allocation refers to how management decides to spend and invest the company's cash. Analyzing the three primary categories of cash flow reveals a company's true operational strategy:
What to look for: Is the company bootstrapping (funding growth solely from operating cash)? Are they borrowing to fund aggressive expansion or dividends? Or are they capital raising by issuing new shares, potentially diluting your ownership? A healthy, mature company typically generates strong operating cash, moderately invests in growth, and returns the surplus to shareholders through financing activities.
Net assets attributable to each share — the accounting floor of intrinsic value
Why Book Value per Share Matters
Book value per share is the net worth of the company — total assets minus total liabilities — divided by shares outstanding (split-adjusted). It represents the theoretical liquidation value per share if every asset were sold and every liability repaid at balance-sheet carrying values. It is the accounting foundation upon which much of equity valuation is built.
A steadily rising book value per share is one of the most reliable signals of compounding wealth creation. It means the company is retaining earnings and building net worth faster than it is returning capital or eroding it. Warren Buffett famously tracked Berkshire Hathaway's book value per share for decades as his primary measure of intrinsic value growth.
Context is essential. Asset-heavy businesses (banks, manufacturers, utilities) should be judged by book value more directly than asset-light businesses (software, consumer brands), where intangible assets like intellectual property and customer loyalty may far exceed their balance-sheet carrying values. A company trading at a large premium to book value is not necessarily overvalued — it may simply possess competitive advantages that accounting rules do not capture. Conversely, a declining book value per share — especially over multiple years — is a serious warning sign of capital destruction.
How much of the company is financed by debt versus shareholders' equity
Reading the Debt-to-Equity Ratio
The debt-to-equity (D/E) ratio compares total financial debt to shareholders' equity. A ratio of 1.0 means the company has borrowed one dollar for every dollar of equity; a ratio of 2.0 means it has borrowed twice as much as it owns. Financial leverage amplifies both returns and risk: in good times, debt turbocharges equity returns; in bad times, it accelerates losses and can threaten solvency.
Trends matter more than a single number. A rising D/E ratio can mean the company is taking on debt to fund growth — potentially value-creating if returns exceed the cost of capital. But it can also mean equity is being eroded through losses or that the business is borrowing simply to sustain operations. A falling D/E ratio generally reflects strengthening financial health: earnings are being retained, debt maturities are being paid down, or both.
Industry norms vary enormously. Capital-intensive sectors (utilities, real estate, financials) routinely carry high D/E ratios that would be alarming in, say, a technology company. Always compare against sector peers. As a rough rule of thumb, a D/E above 2× in a cyclical business warrants careful scrutiny of interest coverage and refinancing risk.
Short-term liquidity — can the company cover its near-term obligations?
Liquidity: Can the Business Pay Its Bills?
The current ratio is calculated as current assets divided by current liabilities. A ratio of 1.5 means the company has $1.50 of short-term assets — cash, receivables, inventory — for every $1.00 of obligations due within the next twelve months. It is the most direct measure of near-term financial resilience: can the business meet its obligations without needing to raise new capital or sell long-term assets at a discount?
A ratio above 1.0 is generally healthy, meaning current assets exceed current liabilities. A ratio consistently above 2.0 may indicate the company is holding excess cash or inventory that could be deployed more productively. A ratio below 1.0 is a warning sign — the company is relying on future cash generation or external financing to cover its near-term obligations, which is manageable in normal conditions but dangerous during a downturn.
Trends and context matter.A declining current ratio isn't always alarming — highly efficient businesses (e.g., large retailers with reliable daily cash flows) often run leaner balance sheets intentionally. Conversely, a rapidly rising current ratio can signal slowing sales causing inventory to build, or customers taking longer to pay. Always compare the trend against industry peers and cross-reference with the cash flow statement to assess whether the business is genuinely liquid or just holding non-cash current assets.
How much the market is paying for each dollar of company earnings
Cigna Group's trailing twelve-month P/E rose sharply into 2024, reaching mid-to-high 20s. The specific values include 25.4x on 2024-03-31, 22.1x on 2024-06-30, and a peak of 27.8x on 2024-09-30. Subsequently, the P/E ratio contracted through 2025 to the low-teens, with the most recent three quarters showing a material decline from the 2024 spike to 12.4x as of the 2025-12-31 period, indicating a reversal of the 2024 re-rating in the latest reported period.
Looking further back, the P/E ratio was generally in a 10–15x range across 2018–2023, with notable troughs during 2020–2021, including 6.4x on 2021-09-30. The sequence shows a sustained increase into 2024, followed by a return toward the historical mid-teens or low-teens level by the end of 2025. The most recent Price-to-Earnings ratio was 12.4x.
What Is the PE Ratio?
The Price-to-Earnings (PE) ratio is one of the most widely used valuation metrics in investing. It divides the current stock price by the company's earnings per share (EPS), revealing how much investors are willing to pay for each dollar of earnings. A high PE can signal that the market expects strong future growth, while a low PE may suggest undervaluation—or reflect genuine concerns about the company's prospects.
Context matters:PE ratios vary significantly across industries. High-growth technology companies routinely trade at PE ratios above 30x or 40x, while mature, low-growth sectors like utilities or financials often trade closer to 10–15x. Always compare a company's PE to its own history and its industry peers, not just an absolute number.
What to Look For:
Key Insight:The PE ratio is a snapshot of market sentiment and expectations. Tracking it over time alongside earnings trends reveals whether the market's valuation has expanded or contracted—and whether that change is justified by fundamentals.